FLB Stock Overview
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$3.59 |
| 52 Week Low | US$0.92 |
| Beta | 1.31 |
| 1 Month Change | 72.27% |
| 3 Month Change | 58.75% |
| 1 Year Change | -32.65% |
| 3 Year Change | -45.42% |
| 5 Year Change | n/a |
| Change since IPO | -83.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| FLB | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.6% | 2.6% | 0.3% |
| 1Y | -32.6% | -19.9% | -11.1% |
Return vs Industry: FLB underperformed the German Life Sciences industry which returned -18.5% over the past year.
Return vs Market: FLB underperformed the German Market which returned -10.1% over the past year.
Price Volatility
| FLB volatility | |
|---|---|
| FLB Average Weekly Movement | 14.1% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FLB is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: FLB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 615 | Michael Egholm | https://www.fluidigm.com |
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Standard BioTools Inc. Fundamentals Summary
| FLB fundamental statistics | |
|---|---|
| Market Cap | €150.59m |
| Earnings (TTM) | -€164.73m |
| Revenue (TTM) | €100.66m |
1.5x
P/S Ratio-0.9x
P/E RatioIs FLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLB income statement (TTM) | |
|---|---|
| Revenue | US$109.19m |
| Cost of Revenue | US$98.00m |
| Gross Profit | US$11.19m |
| Other Expenses | US$189.87m |
| Earnings | -US$178.68m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.25 |
| Gross Margin | 10.25% |
| Net Profit Margin | -163.64% |
| Debt/Equity Ratio | 26.0% |
How did FLB perform over the long term?
See historical performance and comparison